文献速递肝胆胰外科胃肠外科

十二指肠腺癌与肠型壶腹部癌根治性切除术后辅助治疗的作用

The Role of Adjuvant Therapy in Duodenal Adenocarcinoma and Intestinal Subtype Ampullary Carcinoma After Curative Resection.
PubMed 文献 · Ann Surg · 2023-10-13

本研究纳入2010至2021年间在5个高容量中心接受根治性手术的136例十二指肠腺癌(DAC)和171例肠型壶腹部癌(iAC)患者,评估辅助治疗的作用。DAC患者肿瘤分期更晚,中位总生存(OS)为101个月对iAC的155个月(P=0.098)。辅助治疗未能改善所有DAC和iAC患者的OS,但在DAC伴神经周围侵犯以及iAC伴T3-T4、淋巴结阳性、神经周围侵犯的患者中改善了OS。

要点

  • DAC患者较iAC患者肿瘤分期更晚,局部复发率14.1%对1.2%(P<0.001),全身复发率30.4%对3.5%(P<0.001)。
  • 辅助治疗未能改善所有DAC和iAC患者的总生存。
  • DAC伴神经周围侵犯者接受辅助治疗中位OS为72个月对44个月(P=0.044)。

核心结论

  • 在本研究中,辅助治疗未能改善所有DAC和iAC患者的总生存,但改善了DAC伴神经周围侵犯患者以及iAC伴T3-T4肿瘤、阳性淋巴结和神经周围侵犯患者的总生存。

研究设计与样本

  • 研究纳入2010至2021年间在5个高容量中心接受根治性意向手术切除的DAC和iAC患者,评估基线、围手术期及长期肿瘤学结局,使用SPSS 25进行统计检验。

主要发现

  • 共纳入136例DAC患者和171例iAC患者,DAC患者肿瘤分期较iAC更晚。
  • DAC患者中位总生存为101个月,iAC患者为155个月(P=0.098)。
  • DAC患者局部复发率为14.1%,iAC患者为1.2%(P<0.001);DAC患者全身复发率为30.4%,iAC患者为3.5%(P<0.001)。
  • DAC伴神经周围侵犯患者接受辅助治疗中位OS为72个月,未接受辅助治疗为44个月(P=0.044)。
  • iAC伴N+患者接受辅助治疗中位OS为190个月,未接受为57个月(P=0.003);伴T3-T4肿瘤者为177个月对59个月(P=0.050);伴神经周围侵犯者为150个月对59个月(P=0.019)。

关键数值与推荐

  • DAC伴神经周围侵犯:辅助治疗组中位OS 72个月 vs 未辅助治疗组44个月(P=0.044)。
  • iAC伴N+:辅助治疗组中位OS 190个月 vs 未辅助治疗组57个月(P=0.003)。
  • iAC伴T3-T4:辅助治疗组中位OS 177个月 vs 未辅助治疗组59个月(P=0.050)。
  • iAC伴神经周围侵犯:辅助治疗组中位OS 150个月 vs 未辅助治疗组59个月(P=0.019)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the role of adjuvant therapy in duodenal adenocarcinoma (DAC) and intestinal subtype ampullary carcinoma (iAC). BACKGROUND: DAC and iAC share a similar histologic differentiation but the benefit of adjuvant therapy remains unclear. METHODS: Patients undergoing curative intent surgical resection for DAC and iAC between 2010 and 2021 at 5 high-volume centers were included. Patient baseline, perioperative, and long-term oncological outcomes were evaluated. Statistical testing was performed with SPSS 25 (IBM). RESULTS: A total of 136 patients with DAC and 171 with iAC were identified. Patients with DAC had more advanced tumors than those with iAC. Median overall survival (OS) in patients with DAC was 101 months versus 155 months for patients with iAC ( P = 0.098). DAC had a higher rate of local (14.1% vs 1.2%, P < 0.001) and systemic recurrence (30.4% vs 3.5%, P < 0.001). Adjuvant therapy failed to improve OS in all patients with DAC and iAC. For DAC, patients with perineural invasion, but not other negative prognostic factors, had improved OS rates with adjuvant therapy (72 vs 44 m, P = 0.044). Patients with iAC with N+ (190 vs 57 m, P = 0.003), T3-T4 (177 vs 59 m, P = 0.050), and perineural invasion (150 vs 59 m, P = 0.019) had improved OS rates with adjuvant therapy. CONCLUSIONS: While adjuvant therapy fails to improve OS in all patients with DAC and iAC in the current study, it improved OS in patients with DAC with perineural invasion and in patients with iAC with T3-T4 tumors, positive lymph nodes, and perineural invasion.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Finton S, Bolm L, Nebbia M, et al. The Role of Adjuvant Therapy in Duodenal Adenocarcinoma and Intestinal Subtype Ampullary Carcinoma After Curative Resection. Ann Surg. 2023. PMID: 37830246. doi:10.1097/SLA.0000000000006129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。